Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 21, 2026, 9:37 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 193–216 of 685 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Fluid Management Clear all
Withdrawn Not applicable Interventional

Comprehensive Medication Monitoring on Heart Failure Patient Outcomes

NCT03519477
View directory record Official record
Conditions
Heart Failure，Congestive
Interventions
Sano Patient Medication Profile
Diagnostic Test
Lead sponsor
Precera Bioscience, Inc.
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jan 25, 2019 · Synced Oct 21, 2026, 9:37 AM EDT
Terminated Phase 1 Interventional

Umbilical Cord Blood T-Regulatory Cell Infusion Followed by Donor Umbilical Cord Blood Transplant in Treating Patients With High-Risk Leukemia or Other Hematologic Diseases

NCT00376519
View directory record Official record
Conditions
Graft Versus Host Disease, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes, Secondary Myelofibrosis
Interventions
cyclophosphamide, cyclosporine, fludarabine phosphate, mycophenolate mofetil, Treg cell infusion, umbilical cord blood transplantation, total-body irradiation
Drug · Procedure · Radiation
Lead sponsor
Masonic Cancer Center, University of Minnesota
Other
Eligibility
18 Years to 45 Years
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Dec 2, 2017 · Synced Oct 21, 2026, 9:37 AM EDT
Completed Phase 1 Interventional

Poly-ICLC (Hiltonol®) Vaccine In Malignant Pleural Mesothelioma

NCT04525859
View directory record Official record
Conditions
Malignant Pleural Mesothelioma
Interventions
Safety, Expansion Cohort
Biological
Lead sponsor
Oncovir, Inc.
Industry
Eligibility
Not listed
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2025
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jun 24, 2025 · Synced Oct 21, 2026, 9:37 AM EDT
Not listed Not applicable Interventional Accepts healthy volunteers

Enhanced Recovery After Surgery in Kidney Transplant Donors

NCT04110080
View directory record Official record
Conditions
Opioid Use, Kidney Diseases, Pain, Postoperative, Postoperative Complications, Postoperative Nausea and Vomiting
Interventions
multimodal pain management, goal directed fluid management, preoperative carbohydrate loading, Donor nephrectomy, regional anesthesia
Procedure · Other
Lead sponsor
Thomas Jefferson University
Other
Eligibility
18 Years and older
Enrollment
42 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2023
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Apr 18, 2023 · Synced Oct 21, 2026, 9:37 AM EDT
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers Results available

A Pilot Study to Evaluate the Role of High-dose Ranibizumab (2.0mg) in the Management of AMD in Patients With Persistent/Recurrent Macular Fluid Less Than 30 Days Following Treatment With Intravitreal Anti-VEGF Therapy (the LAST Study)

NCT01115556
View directory record Official record
Conditions
Age Related Macular Degeneration
Interventions
Ranibizumab
Drug
Lead sponsor
Vitreous -Retina- Macula Consultants of New York
Other
Eligibility
50 Years and older
Enrollment
9 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2012
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated May 3, 2018 · Synced Oct 21, 2026, 9:37 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Pharmacokinetic Study in Cerebral Spinal Fluid After a Single Dose of AVI-4020

NCT00387283
View directory record Official record
Conditions
West Nile Virus
Interventions
AVI-4020 Injection
Drug
Lead sponsor
Sarepta Therapeutics, Inc.
Industry
Eligibility
18 Years to 64 Years · Male only
Enrollment
14 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2009
U.S. locations
1
States / cities
Tacoma, Washington
Source: ClinicalTrials.gov public record
Updated Jul 8, 2009 · Synced Oct 21, 2026, 9:37 AM EDT
Completed Early Phase 1 Interventional

A Pilot Study of Human Amniotic Fluid for COVID19 Associated Respiratory Failure

NCT04319731
View directory record Official record
Conditions
SARS CoV-2 Infection
Interventions
Human Amniotic Fluid
Biological
Lead sponsor
University of Utah
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Apr 24, 2023 · Synced Oct 21, 2026, 9:37 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Interaction of Alcohol and Highly Active Antiretroviral Therapy (HAART) in HIV/AIDS and HIV/AIDS With Hepatitis C Virus (HCV) Co-Infection

NCT00879047
View directory record Official record
Conditions
HIV Infections, Hepatitis C
Interventions
Alcohol, Alcohol placebo
Drug
Lead sponsor
University of California, San Francisco
Other
Eligibility
21 Years and older
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2013
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated May 6, 2014 · Synced Oct 21, 2026, 9:37 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Escitalopram Effects on CSF Amyloid Beta

NCT02161458
View directory record Official record
Conditions
Amyloid Beta Protein
Interventions
Escitalopram 20mg for 2 weeks, Escitalopram 20mg for 8 weeks, Escitalopram 30mg for 8 weeks, Placebo
Drug
Lead sponsor
University of Pennsylvania
Other
Eligibility
60 Years to 85 Years
Enrollment
98 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2019
U.S. locations
2
States / cities
St Louis, Missouri • Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Apr 9, 2020 · Synced Oct 21, 2026, 9:37 AM EDT
Recruiting Phase 2 Interventional

Evaluation of Treatment Predictors Reflecting Beta-catenin Activation in Hepatocellular Carcinoma

NCT04965454
View directory record Official record
Conditions
Hepatocellular Carcinoma Non-resectable
Interventions
Fluorine-18 fluorocholine
Combination Product
Lead sponsor
Queen's Medical Center
Other
Eligibility
18 Years and older
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2028
U.S. locations
1
States / cities
Honolulu, Hawaii
Source: ClinicalTrials.gov public record
Updated Aug 12, 2026 · Synced Oct 21, 2026, 9:37 AM EDT
Completed Early Phase 1 Interventional Accepts healthy volunteers Results available

Pharmacokinetic Drug-Drug Interaction Study to Identify Biomarkers of Kidney Transporters

NCT05365451
View directory record Official record
Conditions
Interaction, Endogenous Biomarkers
Interventions
MetFORMIN Oral Solution, Cimetidine 400 MG, Furosemide Oral Liquid Product, Probenecid 500 MG
Drug
Lead sponsor
Washington State University
Other
Eligibility
18 Years to 65 Years
Enrollment
16 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2023
U.S. locations
1
States / cities
Spokane, Washington
Source: ClinicalTrials.gov public record
Updated Aug 8, 2025 · Synced Oct 21, 2026, 9:37 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Lactated Ringer's Versus Normal Saline for Acute Pancreatitis

NCT03642769
View directory record Official record
Conditions
Pancreatitis, Acute
Interventions
Fluid administration
Other
Lead sponsor
University of Southern California
Other
Eligibility
18 Years and older
Enrollment
121 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2021
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Dec 8, 2021 · Synced Oct 21, 2026, 9:37 AM EDT
Completed Phase 3 Interventional

A Prospective Randomized Controlled Clinical Trial of Standard Versus Goal-Directed Perioperative Fluid Management (GDT) for Patients Undergoing Radical Cystectomy

NCT02145871
View directory record Official record
Conditions
Bladder Cancer
Interventions
standard fluid management, fluid management guided by the EV1000
Other
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
21 Years and older
Enrollment
282 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2024
U.S. locations
5
States / cities
Basking Ridge, New Jersey • Middletown, New Jersey • Commack, New York + 2 more
Source: ClinicalTrials.gov public record
Updated Mar 20, 2024 · Synced Oct 21, 2026, 9:37 AM EDT
Not listed Not applicable Interventional

Comparison of Prevena Negative Pressure Incision Management System vs. Standard Dressing After Vascular Surgery

NCT02389023
View directory record Official record
Conditions
Peripheral Artery Disease, Critical Limb Ischemia, Claudication
Interventions
standard gauze dressing, Prevena Incision Management system
Other
Lead sponsor
University of Vermont Medical Center
Other
Eligibility
18 Years and older
Enrollment
242 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
5
States / cities
Portland, Maine • Boston, Massachusetts • Lebanon, New Hampshire + 1 more
Source: ClinicalTrials.gov public record
Updated Dec 12, 2018 · Synced Oct 21, 2026, 9:37 AM EDT
Completed Phase 3 Interventional Results available

Tralokinumab Monotherapy for Moderate to Severe Atopic Dermatitis - ECZTRA 2 (ECZema TRAlokinumab Trial no. 2)

NCT03160885
View directory record Official record
Conditions
Atopic Dermatitis
Interventions
Tralokinumab, Placebo
Drug
Lead sponsor
LEO Pharma
Industry
Eligibility
18 Years and older
Enrollment
794 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
40
States / cities
Hot Springs, Arkansas • Encinitas, California • Fullerton, California + 35 more
Source: ClinicalTrials.gov public record
Updated Mar 11, 2025 · Synced Oct 21, 2026, 9:37 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers

Impact of Flavors on Nicotine Perception and Self-Administration Via E-cigarettes

NCT04038515
View directory record Official record
Conditions
Nicotine, E-liquid Flavors
Interventions
Nicotine 0 mg/mL, Nicotine 6 mg/mL, Nicotine 12 mg/mL, Nicotine 24 mg/mL, 'Menthol' flavor, 'Menthol/Mint' flavor, 'Green Apple' flavor, 'Watermelon' flavor, 'Unflavored'
Drug · Other
Lead sponsor
Yale University
Other
Eligibility
18 Years to 30 Years
Enrollment
54 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2024
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Aug 5, 2024 · Synced Oct 21, 2026, 9:37 AM EDT
Completed Phase 2 Interventional

An Open Label Study to Examine the Effects of DAS181 Administered by Dry Powder Inhaler (DPI) or Nebulized Formulation in Immunocompromised Subjects With Parainfluenza (PIV) Infection

NCT01924793
View directory record Official record
Conditions
Parainfluenza
Interventions
DAS181-F02 Dry Powder in Bulk, DAS181-F02 Nebulized Formulation Inhaled Dose
Drug
Lead sponsor
Ansun Biopharma, Inc.
Industry
Eligibility
12 Years and older
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2017
U.S. locations
23
States / cities
Duarte, California • Orange, California • Palo Alto, California + 18 more
Source: ClinicalTrials.gov public record
Updated Jul 19, 2017 · Synced Oct 21, 2026, 9:37 AM EDT
Terminated Phase 3 Interventional Accepts healthy volunteers Results available

Study of Monovalent and Bivalent Recombinant Protein Vaccines Against COVID-19 in Adults 18 Years of Age and Older

NCT04904549
View directory record Official record
Conditions
COVID-19
Interventions
SARS-CoV-2 adjuvanted recombinant protein vaccine (monovalent D614) (primary series), SARS-CoV-2 adjuvanted recombinant protein vaccine (bivalent D614 + B.1.351) (primary series), Placebo, SARS-CoV-2 adjuvanted recombinant protein vaccine (monovalent B.1.351) (booster dose) >= 4 months after last vaccination, SARS-CoV-2 adjuvanted recombinant protein vaccine(monovalent D614)(primary series)& SARS-CoV-2 adjuvanted recombinant protein vaccine(monovalent B.1.351)(booster dose)>=4 months after last vaccination
Biological
Lead sponsor
Sanofi Pasteur, a Sanofi Company
Industry
Eligibility
18 Years and older
Enrollment
23,670 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2024
U.S. locations
23
States / cities
Birmingham, Alabama • Huntsville, Alabama • Rolling Hills Estates, California + 20 more
Source: ClinicalTrials.gov public record
Updated Jun 3, 2026 · Synced Oct 21, 2026, 9:37 AM EDT
Active, not recruiting Not applicable Interventional Accepts healthy volunteers

A Practice-Based Intervention To Improve Care for a Diverse Population Of Women With Urinary Incontinence

NCT05534412
View directory record Official record
Conditions
Urinary Incontinence
Interventions
Academic Detailing, Electronic Clinical Decision Support, APP Co-management, Electronic Referral
Other
Lead sponsor
University of California, San Diego
Other
Eligibility
18 Years and older
Enrollment
1,600 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2027
U.S. locations
4
States / cities
La Jolla, California • Los Angeles, California • Torrance, California
Source: ClinicalTrials.gov public record
Updated Mar 13, 2026 · Synced Oct 21, 2026, 9:37 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Behavior Enhances Drug Reduction of Incontinence (BE-DRI)

NCT00090584
View directory record Official record
Conditions
Urinary Incontinence (UI)
Interventions
Tolterodine, Behavioral training
Drug · Behavioral
Lead sponsor
Carelon Research
Other
Eligibility
21 Years and older · Female only
Enrollment
307 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2004 – 2006
U.S. locations
9
States / cities
Birmingham, Alabama • San Diego, California • Maywood, Illinois + 6 more
Source: ClinicalTrials.gov public record
Updated Jun 17, 2013 · Synced Oct 21, 2026, 9:37 AM EDT
Not yet recruiting Early Phase 1 Interventional Accepts healthy volunteers

Evaluating the Delivery and Effects of THC Vaping Liquids in the Bloodstream

NCT06334016
View directory record Official record
Conditions
Cannabis Dependence
Interventions
Biospecimen Collection, Cannabis sativa Extract, Nicotine, Placebo Administration, Questionnaire Administration
Procedure · Drug · Other
Lead sponsor
Roswell Park Cancer Institute
Other
Eligibility
21 Years and older
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2028
U.S. locations
1
States / cities
Buffalo, New York
Source: ClinicalTrials.gov public record
Updated Sep 25, 2026 · Synced Oct 21, 2026, 9:37 AM EDT
Active, not recruiting Phase 3 Interventional

Study to Evaluate Avacopan in Combination With a Rituximab or Cyclophosphamide-containing Regimen, in Children From 6 Years to < 18 Years of Age With AAV.

NCT06321601
View directory record Official record
Conditions
Vasculitis
Interventions
Avacopan
Drug
Lead sponsor
Amgen
Industry
Eligibility
6 Years to 17 Years
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
10
States / cities
Atlanta, Georgia • Indianapolis, Indiana • Minneapolis, Minnesota + 7 more
Source: ClinicalTrials.gov public record
Updated Jul 20, 2026 · Synced Oct 21, 2026, 9:37 AM EDT
Completed Phase 1 Interventional Results available

Three Way Crossover Closed Loop Study With Xeris Glucagon

NCT03424044
View directory record Official record
Conditions
Type1diabetes
Interventions
Artificial Pancreas Controller in Dual Hormone Mode, Artificial Pancreas Controller in Single Hormone Mode, Artificial Pancreas Controller in Predictive Low Glucose Suspend Mode, XeriSol glucagon
Device · Drug
Lead sponsor
Oregon Health and Science University
Other
Eligibility
21 Years to 50 Years
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated May 27, 2020 · Synced Oct 21, 2026, 9:37 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

The Bioequivalence of Atripla in an Oral Liquid Formulation Compared With the Tablet Formulation in Healthy Volunteers

NCT00862823
View directory record Official record
Conditions
Healthy
Interventions
tenofovir, emtricitabine and efavirenz fixed dose tablet, tenofovir, emtricitabine and efavirenz tablet added to solution
Drug
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
19 Years to 65 Years
Enrollment
14 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2010
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Sep 14, 2012 · Synced Oct 21, 2026, 9:37 AM EDT